Edge
StocktwitsEarnings

Official STOCKTWITS Representative

$NTLA Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.80 up 18.37% YoY
• Reported revenue of $7.66M down -46.23% YoY
• Intellia Therapeutics expects FDA acceptance of its biologics license application for lonvo-z in the second half of 2026 and plans to launch lonvo-z commercially in the first half of 2027.Price since post
Advertisement|Remove ads.